Today, we would like to share an important update regarding our executive leadership team. After thoughtful consideration, Tom Smale will no longer be fulfilling the role of Chief Operating Officer at Klonetics.
Tom's departure comes as a result of a shared understanding that the demands of his other responsibilities have made it increasingly challenging for him to dedicate the 100% commitment we require from our C-level executives. Tom's passion and energy have been divided between Klonetics and his own ventures, and to ensure that we can continue to serve our customers and shareholders to the best of our abilities, we have made the difficult decision to part ways. We believe this decision is in the best interest of both Tom and the future of Klonetics.
As many of you are aware, Klonetics has been experiencing significant growth and success over the past few months, not only here in Canada, but Internationally. For this reason, it is imperative that we have a leadership team that is able to give their full attention to this significant growth phase as our needs become greater, and our scale increases.
Klonetics has bolstered our team, by adding a sophisticated and dedicated Cultivation Lead with an extensive background in the cannabis industry.
Effective immediately, we are thrilled to announce that Natasha Shumka, who has been an integral part of our leadership team for the last 6 months, will assume the role of Chief Operating Officer. Natasha's dedication, expertise, and deep understanding of our company's strategic goals make her the ideal candidate to lead our operations as we continue on our path of growth and innovation.
We are excited about the opportunities in front of us and are committed to delivering the same level of excellence and innovation that you have come to expect from Klonetics. We would like to express our deepest gratitude to Tom for his contributions at Klonetics over the past 15 months and wish him all the best with his future projects and adventures.
Thank you for your continued support and trust in Klonetics as we continue to evolve and grow into a global cannabis company, backed by science.
This three-year project aims to develop the optimal media formulations and transformation process to generate the highest-value cannabis plants in the market. We have examined the response of different cannabis genotypes to tissue culture media formations to develop tissue culture media formulations tailored for cannabis genotypes. We will be evaluating upon flowering of the rooted clones of the selected tissue culture plants, flowers should have equal to or better yield and potency than traditional clone production and cultivation of cannabis plants.
Another goal of this project is to develop a genetic transformation procedure for cannabis from callus and/orprotoplast regeneration optimization. This protocol will be used to increase pathogen resistance and improve quality traits like yield in cannabis plants.
Abstract: First, the project will focus on the genetic structure of a subset of Klonetic's extensive germplasm collection by conducting a large genotyping-by-sequencing (GBS) experiment and single nucleotide polymorphism (SNP) data analyses. Second, the project will perform phenotypic analyses at the CLS (Canadian Light Source) to quantify important biochemical and agronomic traits associated with trichomes and seed formation.
Description: Due to longstanding restrictions, our basic knowledge of Cannabis is far behind other crops (Clarke and Merlin 2017). Hence, many of the claims made by the industry regarding the various applications of Cannabis require advanced molecular, pharmaceutical, and agronomic research, all of which require an in-depth understanding of its evolutionary history, genetic structure, biochemical variability, and reproductive diversity. This research proposed here provides a roadmap combining modern genomics tools to establish a solid business model for cannabis genetic improvement to cater to future needs of the medical and recreational market in Canada.
Abstract: An integrative research project aimed at studying the pollen generated by a core set of Cannabis accessions is proposed The project will develop phenotypic analyses of pollen at the CLS whereby both surface and internal structures can be qualified and quantified. The project will focus on identifying X and Y chromosomes carrying pollen, as this could be used in a sorting procedure for the directed breeding of female plants.
Description: Medicinal cannabis is a treasure trove of phytochemicals with more than 110 different cannabinoids, terpenes, and flavonoids. Major phytoactive compounds of interest are delta-9 tetrahydrocannabinolic acid (THCA) and cannabidolic acid (CBDA) for their medicinal effects. Varying profiles of THC, CBD, and terpenes with a range of 20-30% total cannabinoids in cannabis products provide numerous opportunities for treating different diseases (medicinal applications) and various organoleptic properties in combination with THC (recreational applications). Most of the traditional cannabis breeding in North America used hybrid or varietal approaches, whereas little efforts have been made to apply modern genomics tools and breeding methods for cannabis genetic improvement and innovation.
All Rights Reserved | Klonetics Plant Science Inc.